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Abstract
Objective: A 2007 study performed at Montefiore Medical Center (Bronx, NY)
identified high prevalence of reduced bone density in an urban population of patients
with epilepsy and suggested that bone mineralization screenings should be regularly
performed for these patients. We conducted a long-term follow-up study to determine whether bone mineral density (BMD) loss, osteoporosis, and fractures have
been successfully treated or prevented.
Methods: In the current study, patients from the 2007 study who had two dualenergy absorptiometry (DXA) scans performed at least 5 years apart were analyzed.
The World Health Organization (WHO) criteria to diagnose patients with osteopenia
or osteoporosis were used, and each patient's probability of developing fractures was
calculated with the Fracture Risk Assessment Tool (FRAX).
Results: The median time between the first and second DXA scans for the 81 patients
analyzed was 9.4 years (range 5-14.7). The median age at the first DXA scan was
41 years (range 22-77). Based on WHO criteria, 79.0% of patients did not have worsening of bone density, while 21.0% had new osteopenia or osteoporosis; many patients
were prescribed treatment for bone loss. Older age, increased duration of anti-epileptic
drug (AED) usage, and low body mass index (BMI) were risk factors for abnormal
BMDs. Based on the first DXA scan, the FRAX calculator estimated that none of the
patients in this study had a 10-year risk of more than 20% for developing major osteoporotic fracture (hip, spine, wrist, or humeral fracture). However, in this population,
11 patients (13.6%) sustained a major osteoporotic fracture after their first DXA scan.
Significance: Despite being routinely screened and frequently treated for bone mineral density loss and fracture prevention, many patients with epilepsy suffered new
major osteoporotic fractures. This observation is especially important as persons
with epilepsy are at high risk for falls and traumas.
KEYWORDS
bone mineral density, dual-energy absorptiometry scan, fracture, Fracture Risk Assessment Tool,
osteoporosis
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IN T RO D U C T IO N

Persons with epilepsy are at an increased risk of sustaining
fractures.1–4 A large meta-analysis that compared the fracture risk for persons with and without epilepsy showed that
the relative risk of having any fracture for persons with epilepsy is doubled, and it is fivefold and sixfold for hip and
spine fractures, respectively.5 The determination of why persons with epilepsy maintain a higher fracture risk remains
inconclusive. Prior studies have revealed that fractures can
be directly caused from seizure-related falls and trauma.6,7
Several studies have shown that duration of anti-epileptic
drug (AED) treatment increases fracture risk,1,8–10 while
other studies show that only current and recent AED usage
affects fracture risk.11 It remains unclear whether taking certain types of AEDs, namely enzyme-inducing AEDs, elevates
one's fracture risk and to what degree.5,9,11 It is also unclear
how gender-specific and concurrent disease impacts fracture
risk.1,4,9,12 Calcium and vitamin D are common supplements
for bone density loss prevention; however, the evidence for
their efficacy in the prevention of osteoporotic fractures is
limited.13 There are multiple studies that show the efficacy
of bisphosphonates in maintaining bone density loss and in
fracture risk reduction.14
A 2007 study performed at our institution—Comprehensive
Epilepsy Center, Montefiore Medical Center (Bronx, NY),
identified high prevalence of reduced bone mineral density
(BMD) in an urban population of persons with epilepsy.15
Out of the 130 patients included in this Montefiore study,
55% presented with T-scores less than or equal to −1. The
study showed that certain risk factors, such as specific AED
usage, duration of AED treatment, gender, and age, increase
the likelihood of having an abnormal BMD. The study suggested that bone mineralization screenings should be regularly performed for these patients.
This long-term follow-up study was conducted to determine whether BMD loss, osteoporosis, and fractures have
been successfully treated or prevented in our clinic setting. Another goal of this study was to determine whether
certain risk factors and patient characteristics can predict
whether a person with epilepsy will develop or maintain
an abnormal BMD or suffer a fracture over an extended
period of time.
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Study design

This retrospective study analyzes data obtained from patients involved in the initial 2007 study. In the current study,
patients were included if they had a follow-up dual-energy
absorptiometry (DXA) scans performed at least 5 year after

Key Points
• This long-term study assesses whether osteoporosis and fractures have been effectively treated or
prevented in persons with epilepsy.
• Based on WHO criteria, 21.0% of subjects developed new osteopenia or osteoporosis.
• Older age, increased duration of anti-epileptic
drug usage, and low BMI were risk factors for abnormal bone mineral density.
• The FRAX Calculation Tool underestimated risk
of fracture in this patient population.

the initial one. Patients’ BMDs at the initial and follow-up
scans were compared, and patient charts were reviewed to
determine whether they sustained a major osteoporotic fracture since the original study. Major osteoporotic fracture was
defined as a fracture at one of these sites: hip, spine, wrist, or
humerus. Changes in BMDs were analyzed in relation to various potential risk factors, and the Fracture Risk Assessment
Tool (FRAX) was used to calculate the 10-year risk of suffering a major osteoporotic fracture.

2.2
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Data sources

Patient information was collected from the 2007 study database and from follow-up chart review. All the patients were
adults who received care at the Comprehensive Epilepsy
Center at Montefiore Medical Center, which is an urban
hospital that serves a predominantly low-income and demographically diverse population. Data gathered included demographics, T-scores from the two DXA scans performed,
type of AEDs, and bone loss treatment (calcium, vitamin D,
bisphosphonates, or a combination of these treatments) taken
at the initial and follow-up DXA scans.

2.3

|

Bone mineral density (BMD)

Each patient's BMD was measured using DXA scans and reported in the form of T-scores and Z-scores. T-score is defined as the standard deviation of an individual's BMD from
the mean value for healthy young white women. Z-score represents the number of standard deviations from the normal
mean value for age-, race- or ethnicity-, and sex-matched control subjects.16 According to the World Health Organization
(WHO), a T-score ≥ −1 is considered normal, a T-score between −1 and −2.5 is defined as osteopenia or low bone density, and a T-score ≤ −2.5 is defined as osteoporosis.17 In this
study, patients’ femoral neck T-scores were used.
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FRAX calculation tool

The FRAX Calculation Tool was developed by the University
of Sheffield to estimate a person's 10-year probability of suffering a major osteoporotic fracture.18,19 The FRAX incorporates
clinical risk factors, such as previous fracture, alcohol consumption, current smoking, and BMD of the femoral neck. The
calculator has models that are population-specific to different
nationalities and ethnicities all around the world. For the United
States, the FRAX differentiates ethnicity into four demographic
categories: Caucasian, Black, Hispanic, and Asian. In the
United States, postmenopausal women and men aged 50 years
or older who have a major osteoporotic fracture risk ≥ 20% in
the next 10 years qualify for treatment with antiresorptive or anabolic osteoporotic medication as appropriate.20,21 In this study,
the FRAX Calculation Tool was used to calculate each patient's
10-year risk of suffering a major osteoporotic fracture, and the
tool's ability to successfully identify persons with epilepsy who
have a high fracture risk and to predict which patients would
ultimately sustain a fracture was assessed.

|

2.5

Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics
Version 24, IBM Corp. Risk factors for low BMD and
fractures were compared using Mann-Whitney U test and
Kruskal-Wallis test for nonparametric data. Fisher's exact
test was used for analysis of distribution of variables.
This study was conducted with the approval of the
Montefiore Medical Center Institutional Review Board.
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Demographic data

Of the 130 patients enrolled in the 2007 Montefiore study, 81
patients (62.3%) had at least one follow-up DXA scan more
than 5 years after their first DXA and were included in the
current analysis. For the 81 subjects with complete data, the
median time between the first and second DXA scans was
9.4 years (range 5-14.7 years). The patients’ demographic
data are displayed in Table 1. 54.3% of the patients were female. Patient median age at initial DXA scans was 41 years
(range 22-77 years) and was 52 years (range 29-88 years)
at their follow-up DXA scans. The patients enrolled in this
study were racially diverse as indicated.
Of the remaining 49 subjects who were in the initial 2007
cohort and not part of the current study, 31 did not have a
repeat DXA scan or had their repeat DXA less than 5 years
apart after first. The rest were lost to follow-up or insufficient
information was available. For the 31 patients at their initial

TABLE 1

Demographic data (total sample size: 81 patients)
Value (% of total population)

Gender

Female (54.3), male (45.7)

Race

Asian (3.7), Black (35.8),
Hispanic (35.8), Caucasian
(24.7)

WHO clinical status (femoral neck)
Normal at both DXA scans

44.4

Osteopenia at both DXA
scans

19.8

Osteoporosis at both DXA
scans

1.2

Normal to osteopenia

8.6

Normal to osteoporosis

1.2

Osteopenia to normal

8.6

Osteopenia to osteoporosis

11.1

Osteoporosis to osteopenia

4.9

Secondary osteoporosis (at any site)
Never

70.4

At both DXA scans

7.4

Only at first DXA scan

8.6

Developed after first DXA
scan

13.6

Smoker

1st DXA
scan

2nd DXA
scan

11.1

8.6

Taking glucocorticoids

1.2

4.9

Rheumatoid arthritis

1.2

2.5

Alcohol consumption:> 3
units/day

1.2

1.2

Value
Median BMI at second DXA
Scan (kg/m2)

27.2

Median time between DXA
scans in years (range)

9.4 (5-14.7)

FRAX score—major
osteoporotic fracture risk
(median, range)

1.4% (0.5%-14%)

Median age in years (range)

1st DXA
Scan

2nd DXA
Scan

41 (21-77)

52 (29-88)

DXA scan, the average age was 39.6, 54.8% were female, and
3.2% (one patient) had osteoporosis.

3.2
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Osteoporosis/T-scores

Based on WHO criteria, 44 (54.3%) of the 81 patients included in this study had normal BMD, 32 (39.5%) had
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osteopenia, and five patients (6.2%) had osteoporosis at their
first DXA scan (femoral neck).
Overall, 79.0% of patients had stable or improved WHO
status (femoral neck) between the DXA scans. Of the 44
patients who had normal BMDs at their first DXA scans,
36 (81.8% of all normal patients) continued to have normal
BMDs at the second DXA scan; seven osteopenic patients
(21.8% of all osteopenic patients) improved to normal bone
density and 16 patients (50%) remained osteopenic; four
patients (80% of all patients with osteoporosis) improved
from osteoporosis to osteopenia. At the second DXA scan,
three patients (8.8%) out of the 34 who were below the age
of 50 had osteoporosis; 14 patients (29.7%) out of the 47
patients who were 50 and older had osteoporosis. Figure 1
shows the change in BMD from the first to their second
DXA scan. Overall, 45 patients (55.6%) had a lower T-score
at the femoral neck at their second DXA scan than at their
initial one.

3.3 | AEDs and bone density loss
supplements

Comparison of patient medications at both DXA scans
Value (% of total population)
a

Taking AEDs known to decrease BMD

1st DXA scan

2nd DXA scan

86.4

80.2

46.9

44.4

1.2

2.5

9.9

27.2

42.0

25.9

Bone loss treatment
Calcium/vitamin D
Bisphosphonates
Calcium/vitamin D and bisphosphonates
No treatment/cannot obtain results

Value (%)

% of patients taking AEDs known to decrease BMD treated with bone loss treatment

a

243

At the time of the first DXA, 86.4% of patients were taking AEDs known or suspected to decrease BMD (benzodiazepines, valproic acid, zonisamide, and enzyme-inducing
AEDs: carbamazepine, phenytoin, oxcarbazepine, topiramate, and phenobarbital). Although gabapentin does not
have liver effects, it appears to also reduce BMD, and it
was therefore included with other AEDs known to decrease BMD in the analysis.2 AEDs that are not considered to influence bone metabolism include lamotrigine,
levetiracetam, and lacosamide.2 46.9% of patients were
only taking calcium and vitamin D, and 11.1% were taking
bisphosphonates alone or in combination with calcium and
vitamin D (Table 2).
At the time of the second DXA, 80.2% of all patients
were taking AEDs known to decrease BMD and 74.1% were

F I G U R E 1 Comparison of BMD at
both DXA scans: Horizontal axis represents
WHO status at DXA 1, and vertical axis
represents WHO status at DXA2. In the
graph, each circle represents a patient;
numbers represent patients in that group
(% of total population)

TABLE 2

|

1st DXA scan

2nd DXA scan

55.7 (39/70 patients)

76.9 (50/65)

% of patients with abnormal BMD treated with medications for bone loss

89.2 (33/37)

84.2 (32/38)

% of patients with abnormal BMD and on AEDs known to decrease BMD treated with
medications for bone loss

90.3 (28/31)

87.5 (28/32)

Includes benzodiazepines, carbamazepine, phenytoin, valproic acid, gabapentin, oxcarbazepine, topiramate, phenobarbital, and zonisamide
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taking medications to prevent or treat bone loss. The exact
duration of treatment for each specific AED could not be definitively assessed from chart review, and only an aggregate
total length of time that patients took any AED could be analyzed: The median duration of treatment was 21 years at the
first DXA scan and was 32 years at the second DXA scan.
Of the 70 patients who were taking AEDs known to decrease
BMD at the first DXA scan, 55.7% were simultaneously being
treated for bone loss. Of the 65 patients who were taking AEDs
known to decrease BMD at the second DXA scan, 76.9% were
also being treated for bone loss, reflecting a 21.2% increase.
Of the 37 patients who had abnormal BMD at their first DXA
scan, 89.2% were also taking medications to prevent or treat
bone loss. At the second DXA scan, out of 32 patients who took
both AEDs known to decrease BMD and had abnormal BMD,
at least 87.5% were prescribed bone loss treatment.

3.4 | Risk factors for abnormal BMDs and
worsening WHO clinic statuses
Patients who had abnormal BMD at baseline or decline in
WHO status in their follow-up DXA scans were compared
with patients who improved or maintained normal BMD at
follow-up. This first group of patients initially had normal
BMD and subsequently developed abnormal BMD, had osteopenia and developed osteoporosis, had osteopenia at both
DXAs, or had osteoporosis at both examinations. The second
group had normal BMD at both scans, had abnormal BMD
initially and subsequently developed normal BMD, or had
osteoporosis and developed osteopenia. This comparison is
displayed in Table 3A.
Older age was associated with either worsening or persistently abnormal BMD: The median age at the second DXA
scan of this group was 54 years, whereas the median age of patients who improved or maintained normal BMD was 48 years
(P = .017). Low body mass index (BMI) was also positively
correlated with either worsening or persistently abnormal
BMD: The median BMI of patients who had worsening or persistently abnormal BMDs was 25.0 kg/m2 vs 28.3 kg/m2 for
patients who improved or maintained normal BMD (P = .003).
Overall, many patients took AEDs known to decrease
BMD (85.3% of patients who had worsening or persistently
abnormal BMDs vs 87.2% of patients who improved or
maintained normal BMDs). From chart review, duration of
treatment for each specific AED could not be established.
However, the total time the patients took any AED at first
DXA scan could be determined: 29 years for patients who
had worsening or persistently abnormal BMDs vs 19 years for
those who improved or maintained normal BMDs (P = .043).
Gender, smoking, and alcohol intake were not found to be
associated with worsening or persistently abnormal BMD in
this study.

MILLER et al.
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3.5

Fractures and FRAX-calculated risks

The FRAX Calculation Tool was used to compare the patients’ 10-year risk of sustaining a major osteoporotic fracture with the actual incidence of fractures in this population.
The median major osteoporotic fracture risk calculated by
FRAX at the first DXA scan was 1.4% both in men and in
women (range: 0.5%-14%). No patients had a 10-year risk
of a major osteoporotic fracture ≥20%, which is the recommended risk threshold for when treatment should be considered. However, in our study population, 11 patients (13.6%)
sustained a major osteoporotic fracture after their first DXA
scan (Table 3B). Of the 11 patients who sustained a fracture,
3 patients (27.3% of patients in this group) were younger than
50 years old and 8 (72.7% of patients in this group) were
50 years or older. Four patients sustained hip fractures, two
patients had vertebral fractures, one patient had a wrist fracture, two patients had humeral fractures, one patient had a hip
and a vertebral compression fracture at different times, and
one had vertebral, wrist, and humeral fractures. It is unclear
from chart reviews whether these fractures could be attributed to seizure-related falls or to other traumas.
Of the patients with new fractures, nine (81.8%) were taking AEDs known to decrease BMD at their first DXA scan.
Five (45.4%) of the patients with new fractures were taking
calcium or vitamin D alone, and two (18.2%) were taking bisphosphonates at their first DXA scan. Out of the nine patients
who were taking bisphosphonates, two (22.2%) sustained
major osteoporotic fractures and seven did not. No statistically significant correlations were found between individual
risk factors analyzed and incidence of sustaining a fracture.

4

|

DISCUSSION

The study objective was to determine the extent to which reduced BMD and major osteoporotic fractures occurred over
an extended period of time in persons with epilepsy and to
identify any risk factors which may have predicted that outcome. The results demonstrate that 79.0% of the initial population had no significant change in bone mineral density over
an approximately 10-year period; of these, 44.4% had normal
results in both DEXA scans, 13.5% initially had abnormal
BMDs but improved, and nearly 20% showed osteopenia at
both time points.
However, 21.0% of our patients did show worsening in
bone mineral density over the 10-year time frame. Overall,
12.3% of patients developed osteoporosis (femoral neck),
and 13.6% suffered new major osteoporotic fractures. This
occurred despite the observation that most of the patients
who had low BMDs and were taking AEDs known to decrease BMD were consistently treated with bone mineral
density loss treatments. The probability for worsening or
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TABLE 3

(A) Correlation between risk factors and change in WHO clinical status (at femoral neck). (B) Correlation between risk factors and
occurrence of major osteoporotic fractures between DXA scans (after the first DXA and before the second DXA)
A
Abnormal or worsened
WHO clinical status
(osteopenia/osteoporosis)
N = 34 (42.0%)

B
Normal or improved
WHO clinical status
N = 47 (58.0%)

Value (P value)

Sustained major
osteoporotic fracture
N = 11 (13.6%)

Did not sustain major
osteoporotic fracture
N = 70 (86.4%)

Value (P value)

Age at second DXA scan in
years (median)

54

48 (.017)

52

50.5 (.121)

Gender: female/male (%)

58.8/41.2

51.1/48.9 (.489)

54.5/45.5

54.3/45.7 (.987)

Race: Asian/Black/Hispanic/
White (%)

2.9/20.6/41.2/35.3

4.3/46.8/31.9/17

9.1/27.3/27.3/36.4

2.9/37.1/37.1/22.9

BMI in kg/m2 (median)

25.0

28.3 (.003)

25.7

27.3 (.174)

Smoking at 1st DXA (%)

14.7

8.5 (.381)

27.3

8.6 (.067)

Time between DXA scans in
years (median)

10.1

8.6 (.043)

11.3

9.3 (.123)

Took AEDs known to
decrease BMD at 1st DXA
(%)

85.3

87.2 (.801)

81.8

87.1 (.632)

Duration of AED treatment
at 1st DXA in years
(median)

29

19 (.043)

23

21 (1)

FRAX score 1st DXA
(median)

1.6

1.1 (.018)

3.1

1.4 (.018)

Bone Loss treatment at 1st DXA (%)
Calcium/vitamin D

67.7

31.9

45.4

47.1

Bisphosphonates

2.9

0

0

1.4

Calcium/vitamin D and
bisphosphonates

11.8

8.5

18.2

8.6

No treatment/cannot obtain
results

17.6

59.6

36.4

42.9

Bone Loss treatment at 2nd DXA (%)
Calcium/vitamin D

41.2

46.8

Bisphosphonates

5.9

0

Calcium/vitamin D and
Bisphosphonates

35.3

21.3

No treatment/cannot obtain
results

17.6

31.9

maintaining abnormal BMDs was predicted by various
patient characteristics, such as older age, low BMI, and
increased time between DXA scans. Prior studies have
shown that lower BMIs are correlated with an increased
likelihood of developing osteoporosis and maintaining abnormal BMDs.22 Although the relationship between BMI
and a reduced BMD remains inconclusive, some possible
explanations are that a higher BMI/body weight imposes a
greater mechanical load on the bone which leads to an increase of bone mass to accommodate this load.22 It is worth

noting that the estimated prevalence of osteoporosis in the
general population varies between 5.1% (50-59 years old)
and 16.4% (70-79 years old).23 In our population, 8.8% of
patients under the age of 50 and 29.7% of patients who were
50 years and older at the second DXA scan had osteoporosis. Furthermore, in our study 8.8% of patients who were
younger than 50 years old and 17% of patients who were
50 years and older sustained fractures. Although bisphosphonates have been shown to prevent fractures, it is worth
noting that just two (18.2%) of the 11 patients who sustained

246

|   

major osteoporotic fractures were taking bisphosphonates; it
is unclear whether increased usage of bisphosphonates could
have decreased the incidence of major osteoporotic fracture
in this study population.
In this study, the FRAX scores (median 1.4%, with no 10year risk ≥20%) suggested that none of the patients were at
a major risk of sustaining fracture; thus, no treatment recommendations were derived from these scores. The median
FRAX score of 11 patients who ultimately sustained a major
osteoporotic fracture was only 3.4%. Thus, the FRAX severely underestimated the 10-year risk of sustaining a major
osteoporotic fracture in this group of persons with epilepsy.
The FRAX calculator is limited in that it neglects to consider the added risk of fracture for persons who are prone to
falling, accidents, or physical injury.24,25 This observation is
particularly relevant to patients in our clinic setting, as persons with epilepsy are at high risk for falls and trauma,7 and
could explain why the FRAX underestimated the number of
patients who would suffer a fracture. The major osteoporotic
risk threshold of ≥20% for preventative bone loss treatment
appears to be too high a bar for persons with epilepsy, and
treatment should be considered for persons with epilepsy who
present a FRAX major osteoporotic fracture risk less than
20%. Due to the small size of this study, the results should not
be used to quantify the exact percent risk at which persons
with epilepsy should be preventatively treated. Rather, the
results of this study underscore the FRAX’s underestimation
of fracture risk in persons with epilepsy and should be taken
into consideration when making clinical treatment decisions
for persons with epilepsy.
Multiple fracture risk assessment tool exists in addition
to the FRAX, such as Garvan and Qfracture.26 Unlike the
FRAX, both Garvan and Qfracture include falls as an input
risk variable. Out of these three tools, Qfracture is the only
one to include epilepsy or taking anticonvulsants as an additional input risk factor. Previous findings have concluded that
the FRAX calculator is superior to the Qfracture in the setting of Parkinson's disease27 or multiple sclerosis.28 Further
research is needed to evaluate which risk assessment tool
would be superior at predicting incidence of fractures in the
presence of epilepsy.
This study had several limitations. As chart review was
the primary method for data gathering, patient information included in the charts may have been incomplete. For
example, AED usage and bone loss treatment may have
been omitted in the medical records and therefore their
prevalence may have been underreported in the analysis.
There were no aggregate data which could be compiled
regarding the seizure frequency, seizure type, treatment
compliance, AED doses, bone density loss treatment
length, and dose—and their relation to fractures and
other outcomes. Since the time of the study, treatment
guidelines for bone density loss prevention have been

MILLER et al.

proposed.29 Additionally, newer treatments for bone loss,
including Denosumab, were not used in our patients at the
time of the study.13 Improved treatment protocols could
mitigate bone loss in patients with epilepsy in the future.
Additionally, the details regarding the fracture circumstances are limited, and it is unclear whether these could
be attributed to seizure-related falls or other traumas. The
statistical power was limited due to the relatively small
number of patients enrolled in the study, as only 81 met
inclusion criteria for the study and several potential risk
factors such as diet, menopause, family history, and other
medical conditions were unable to be taken into account.
Although attrition bias is possible, the demographics and
osteoporosis prevalence of the excluded patients are similar to the studied cohort and likely do not skew the results significantly. It is not completely clear whether there
were additional reasons for repeat DXA scans other than
routine follow-ups; this may be a bias toward those 81
patients who had repeat DXA scans vs those 49 patients
not analyzed here.
The usage of the FRAX Calculation Tool was further
limited by available patient information. Data about parental
fractures were unable to be gathered and therefore assumed
“no” for “parent fractured hip.” As the FRAX Calculation
Tool only calculates 10-year probability risks for persons between 40 and 90 years of age, for patients younger than 40
the tool automatically calculated the fracture risk at the age
of 40 years. Some studies suggest that women over 50 years
old who have taken bisphosphonates for longer than five
years may have an actual fracture lower than estimated by
the FRAX Calculation Tool.30 As mentioned, we were unable
to determine the exact duration of bisphosphonate treatment,
and therefore, all patients who received bisphosphonates
were included in the study. Despite the FRAX Calculation
Tool's overestimation of this group's fracture risk, the observed incidence of fracture in this population was still much
higher than estimated.
The results of the study showed that the majority of patients with epilepsy had no significant worsening in bone
mineral density over an approximately 10-year period.
However, there were many patients with epilepsy who presented initially with abnormal BMDs and subsequently sustained fractures. This indicates that overall, the patients with
epilepsy maintain an amplified risk of suffering major osteoporotic fractures. We recommend that persons with epilepsy
who present any evidence of BMD loss should be closely
monitored and considered for treatment to prevent further
BMD loss and to prevent fractures. These findings suggest
the need for strict treatment algorithms for persons with epilepsy and any evidence of bone loss. Further studies should
evaluate how to account for additional risk factors which are
specifically pertinent to persons with epilepsy when using the
FRAX calculator in clinical practice.
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